Chemical compound
UR-144 |
|
Trade names | different brandnames, typical example: "TMCP-018", "KM-X1", "UR-144", "MN-001", "YX-17" |
---|
|
Legal status |
|
---|
|
(1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone
|
CAS Number | |
---|
PubChem CID | |
---|
ChemSpider | |
---|
UNII | |
---|
KEGG | |
---|
ChEMBL | |
---|
CompTox Dashboard (EPA) | |
---|
|
Formula | C21H29NO |
---|
Molar mass | 311.469 g·mol−1 |
---|
3D model (JSmol) | |
---|
CCCCCN1C=C(C2=CC=CC=C21)C(=O)C3C(C3(C)C)(C)C
|
InChI=1S/C21H29NO/c1-6-7-10-13-22-14-16(15-11-8-9-12-17(15)22)18(23)19-20(2,3)21(19,4)5/h8-9,11-12,14,19H,6-7,10,13H2,1-5H3 NKey:NBMMIBNZVQFQEO-UHFFFAOYSA-N N
|
NY (what is this?) |
UR-144 (TMCP-018, KM-X1, MN-001, YX-17) is a drug invented by Abbott Laboratories,[2] that acts as a selective full agonist of the peripheral cannabinoid receptor CB2, but with much lower affinity for the psychoactive CB1 receptor.
- ^ Anvisa (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-07-25). Archived from the original on 2023-08-27. Retrieved 2023-08-27.
- ^ WO application 2006069196, Pace JM, Tietje K, Dart MJ, Meyer MD, "3-Cycloalkylcarbonyl indoles as cannabinoid receptor ligands", published 2006-06-29, assigned to Abbott Laboratories